Latest Ratios: P/E Ratio -0.3x · EV/EBITDA N/A · ROE -324.1%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $16M | $18M | — | — | — | — | — |
| Enterprise Value | $18M | $20M | — | — | — | — | — |
| P/E Ratio → | -0.34 | — | — | — | — | — | — |
| P/S Ratio | 19.51 | 21.88 | — | — | — | — | — |
| P/B Ratio | 0.39 | 0.43 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 24.43 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 62.7% | 62.7% | -6749.5% | -322.6% | — | 88.6% | 60.0% |
| Operating Margin | -2333.4% | -2333.4% | -85004.6% | -670885.8% | — | -93.0% | -989.5% |
| Net Profit Margin | -5570.6% | -5570.6% | -86888.6% | -719859.9% | — | -91.3% | -988.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -324.1% | -324.1% | — | -207.8% | -148.6% | -71.4% | -129.2% |
| ROA | -163.5% | -163.5% | -307.1% | -91.2% | -89.4% | -39.0% | -58.3% |
| ROIC | -72.7% | -72.7% | -1168.9% | -258.8% | -319.1% | — | — |
| ROCE | -103.5% | -103.5% | -1418.8% | -111.0% | -114.5% | -71.9% | -126.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.21 | 0.21 | — | 1.79 | 0.59 | 0.35 | 0.03 |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.05 | — | 0.14 | -0.74 | -0.60 | -1.82 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -12.18 | -12.18 | -19.05 | -10.49 | -19.30 | -31.95 | -1161.20 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 2.68 | 2.68 | 0.17 | 2.17 | 6.13 | 1.97 | 1.83 |
| Quick Ratio | 2.68 | 2.68 | 0.17 | 2.16 | 6.13 | 1.97 | 1.83 |
| Cash Ratio | 2.39 | 2.39 | 0.13 | 1.56 | 5.07 | 1.74 | 1.56 |
| Asset Turnover | — | 0.02 | 0.02 | 0.00 | — | 0.44 | 0.06 |
| Inventory Turnover | — | — | — | 0.15 | — | — | — |
| Days Sales Outstanding | — | — | 158.05 | 11935.32 | — | 47.06 | 541.30 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | 5.6% | 5.0% | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 5.6% | 5.0% | — | — | — | — | — |
| Shares Outstanding | — | $5M | $832997 | $512912 | $420621 | $329051 | $263184 |
Strategic Pivot Execution Risk
As reported in financial statements, HYPD trades at a P/S ratio of 18.77, a valuation that appears to reflect speculative interest in its digital asset treasury rather than the underlying medical device business, which has historically struggled to generate meaningful or consistent revenue growth for shareholders.
The current valuation multiple suggests that investors are pricing the company as a crypto-proxy rather than a healthcare entity. This disconnect warrants caution, as the lack of a positive P/E or FCF yield makes it difficult to anchor the stock price to any traditional fundamental valuation framework.
Based on reported figures, HYPD's ROIC has remained deeply negative, frequently oscillating between -7.3% and -81.7% over the last ten quarters, which indicates that the company has consistently failed to generate a return on invested capital that exceeds its cost of funding during its transition.
The inability to achieve positive returns on capital suggests that the company's legacy medical operations were structurally value-destructive. Investors should monitor whether the new validator-based business model can reverse this trend or if it will simply introduce new, equally inefficient capital allocation patterns.
According to recent SEC filings, HYPD's efficiency metrics are highly erratic, with DSO figures reaching as high as 17,458 in 2023Q4, which highlights a profound inability to manage receivables and working capital effectively during the company's radical pivot from medical devices to decentralized finance infrastructure.
The extreme fluctuations in the cash conversion cycle suggest that the company's operational processes are not yet optimized for its new business model. Such volatility often precedes liquidity crunches, as the firm struggles to align its cash inflows with the high fixed costs of its validator operations.
As noted in historical balance sheets, HYPD's leverage profile is characterized by extreme volatility, with D/E ratios peaking at 9.15 in 2024Q1, suggesting that the company has relied heavily on external financing to bridge the gap between its high operating expenses and minimal operational cash flow.
The negative interest coverage ratios across multiple periods indicate that the company is not generating sufficient earnings to service its debt obligations comfortably. This reliance on external capital leaves the firm highly vulnerable to shifts in market sentiment or changes in the cost of debt.
Based on an analysis of the business model, the P/S ratio is the most commonly misapplied metric for HYPD, as it obscures the fact that the company's revenue is currently transitioning from transactional medical device sales to potentially volatile, fair-value-adjusted digital asset rewards and validator fees.
Using P/S to value HYPD ignores the accounting noise introduced by digital asset fair value adjustments, which can artificially inflate or deflate reported revenue. Analysts should instead focus on 'Validator Yield' and 'Treasury NAV' to better understand the company's true economic performance and long-term viability.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HYPD stock.
Hyperion DeFi, Inc.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
Hyperion DeFi, Inc.'s return on equity (ROE) is -324.1%. The historical average is -176.2%.
Based on historical data, Hyperion DeFi, Inc. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Hyperion DeFi, Inc.'s current dividend yield is 5.61%.
Hyperion DeFi, Inc. has 62.7% gross margin and -2333.4% operating margin.